Ytd revenues increase 87% to $1.7 million
Quarterly revenues increase 166% to $734,000
MONTREAL, Nov. 1 /CNW Telbec/ - LMS Medical Systems (TSX: LMZ, AMEX:
LMZ), a healthcare technology company and developer of the CALM(R) clinical
information system and risk management software tools for obstetrics, today
reported revenues for the second quarter of fiscal 2008 ended September 30,
2007. All amounts are in Canadian dollars.
Revenues in Q2 2008 increased by 166% to $735,000 from $276,000 in
Q2 2007. Our recurring maintenance and technical revenues continue to grow
from our installed client base and increased by 36% to $703,000 from $517,000
for the comparative six-month period. Year-to-date revenues increased by 87%
to $1.7 million from $907,000.
In conjunction with seasonally stronger winter and spring quarters (Q3
and Q4) and corporate streamlining of operations, management anticipates
reaching a cash flow break even at the end of the current fiscal year.
Complete results for the second quarter along with Management's
Discussion and Analysis will be released in normal course on or about
November 14th and will be available in Canada at www.sedar.com, in the United
States at www.sec.gov and at www.lmsmedical.com.
LMS is a leader in the application of advanced mathematical modeling and
neural networks for medical use. The LMS CALM(TM) Suite provides physicians,
nursing staff, risk managers and hospital administrators with clinical
information systems and risk management tools designed to improve outcomes and
patient care for mothers and their infants during childbirth.
Except for historical information contained herein, the matters discussed
in this news release are forward-looking statements. Because these
forward-looking statements involve risks and uncertainties, there are
important factors that could cause actual results to differ materially from
those expressed implied by the forward-looking statements including, but
without limitation, economic conditions in general and in the healthcare
market, the demand for and market for our products in domestic and
international markets, our current dependence on the CALM product suite, the
challenges associated with developing new products and obtaining regulatory
approvals if necessary, research and development activities, the uncertainty
of acceptance of our products by the medical community, the lengthy sales
cycle for our products, third party reimbursement, competition in our markets,
including the potential introduction of competitive products by others, our
dependence on our distributors, physician training, enforceability and the
costs of enforcement of our patents, potential infringements of our patents
and the other factors set forth from time to time in the Company's filings
with the United States Securities and Exchange Commission and with the
Canadian Securities Commissions. The Company has no intention of or obligation
to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
For further information:
For further information: Yves Grou, Chief Financial Officer, LMS Medical
Systems Inc., (514) 488-3461 Ext. 238, Fax: (514) 488-1880,